Hoey Investments’s Allogene Therapeutics ALLO Stock Holding History

Hoey Investments’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300	Closed	-$372	–	424
2025 Q3	$372	Hold	300	–	–	﹤0.01%	384
2025 Q2	$339	Hold	300	–	–	﹤0.01%	385
2025 Q1	$438	Hold	300	–	–	﹤0.01%	338
2024 Q4	$639	Hold	300	–	–	﹤0.01%	325
2024 Q3	$699	Hold	300	–	–	﹤0.01%	343
2024 Q2	$699	Hold	300	–	–	﹤0.01%	343
2024 Q1	$1.34K	Buy	+300	New	+$1.25K	﹤0.01%	307

Other funds holding ALLO

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Hoey Investments's ALLO Position: Q4 2025 in Review

Hoey Investments sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 300 shares — an estimated $372 sold.

Hoey Investments first reported a position in ALLO in Q1 2024 and held it in 7 quarters. The position peaked at $1.34K in Q1 2024. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

Hoey Investments reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
Hoey Investments sold 300 Allogene Therapeutics shares in Q4 2025, an estimated $372.
Hoey Investments first reported a position in Allogene Therapeutics in Q1 2024 and held it in 7 quarters.
Hoey Investments's Allogene Therapeutics position peaked at $1.34K in Q1 2024.
172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Hoey Investments's 13F filing for Q4 2025, filed 28 Jan 2026.